|Bid||3.9400 x 1800|
|Ask||4.0000 x 3200|
|Day's Range||3.8621 - 3.9456|
|52 Week Range||1.8000 - 12.4400|
|Beta (5Y Monthly)||1.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.33|
Dynavax Technologies (DVAX) closed the most recent trading day at $4.17, moving +0.72% from the previous trading session.
Shares of the small-cap biotech Dynavax Technologies (NASDAQ: DVAX) lost 22.4% of their value during the month of September, according to data provided by S&P Global Market Intelligence. Dynavax's stock appears to have fallen victim to nothing more than speculators moving on to greener pastures. CpG 1018 is the same adjuvant used in the biotech's FDA-approved hepatitis B vaccine, Heplisav-B. Dynavax is currently collaborating with multiple partners to evaluate this commercial-stage adjuvant as part of a COVID-19 vaccine.
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.